Keystone Dental Inc.
$492.7K 2,005 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Royal Biologics, Inc.
Royal Biologics, Inc. reported $492,361.60 across General Payments, Research, and Ownership to 287 physicians and teaching hospitals across 302 transactions.
- $492.4K Above-median payer
- All-tracks total
- 302 Above-median volume
- Transactions
- 287 Above-median reach
- Recipients
- +$205.3K
- General Payments vs PY2023
Royal Biologics, Inc. reported $492,361.60 across all CMS Open Payments tracks (General + Research + Ownership) to 287 physicians and teaching hospitals in Program Year 2024 - ranking #765 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $415,546.74, averaging $1.7K per recipient.
How Royal Biologics, Inc.'s $492.4K all-tracks total breaks down
Royal Biologics, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
26/100
Total payments
F
15/100
Transaction volume
F
12/100
Physician reach
F
12/100
Payment type diversity
D
63/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer royal-biologics-inc Royal Biologics, Inc.
$492.4K · #765/1,925 · 0.0% industry · PY2024
- TOT $492.4K
- RANK #765
- SHARE 0.0%
- TXN 302
- RCP 287
- CAT 5
- GEN $415.5K
- ΔGEN +$205.3K
- TOP1 16.5%
- PY 2024
Volume peers
Nearest volume peer: Keystone Dental Inc. ($492.7K)
Royal Biologics, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Royal Biologics, Inc.'s CMS-reported General Payments increased by $205.3K (+97.6%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: ROYAL BIOLOGICS, INC.PY2023: ROYAL BIOLOGICS, INC.PY2024: Royal Biologics, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $210,257.70
- PY2024
- $415,546.74
What the Data Shows for Royal Biologics, Inc.
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Royal Biologics, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
56 transactions worth $225.2K make "Royalty or License" the top general-payment category in the 5-category breakdown below, 54.2% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Royal Biologics, Inc. made 5 types of general payments. "Royalty or License" is the largest category at $225.2K, 54.2% of General Payments.
Royal Biologics, Inc. reports 5 general-payment categories - the top three are Royalty or License (54.2%), Consulting Fee (41.4%), and Food and Beverage (2.9%). The remaining 2 categories make up 1.5% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Royal Biologics, Inc. divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Royalty or License | $225.2K | 56 | 54.2% |
| Consulting Fee | $171.9K | 89 | 41.4% |
| Food and Beverage | $12.0K | 133 | 2.9% |
| Travel and Lodging | $5.5K | 1 | 1.3% |
| Entertainment | $926.09 | 8 | 0.2% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $246,203.17 (59.2%) of $415,546.74 in this company's General Payments records across 130 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Royal Biologics, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Raz Winiarsky
$68,400.00 across 13 reported transactions
- 2
Grigoriy Arutyunyan
$60,848.79 across 4 reported transactions
- 3
Robert Wetzel
$41,460.40 across 6 reported transactions
- 4
Brad Prybis
$39,824.91 across 5 reported transactions
- 5
Ki-Hon Lin
$35,669.07 across 6 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Royal Biologics, Inc. ranks #765 of 1,925 by total payments (top 40% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,078 of 1,838 by HHI (bottom 41% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Motiva USA, LLC : $482.1K total payments, HHI 886
- Zambon USA Ltd. : $62.5K total payments, HHI 886
- Asahi Intecc USA, Inc. : $443.1K total payments, HHI 885
- Clariance, Inc. : $125.5K total payments, HHI 882
- Sirona Dental Systems GmbH : $108.6K total payments, HHI 881
- GT Medical Technologies, Inc : $345.6K total payments, HHI 879
- Royal Biologics, Inc. (this company) : $415.5K total payments, HHI 879
- Labcorp Holdings Inc. : $1.2K total payments, HHI 868
- Oxford Gene Technology Inc : $2.3K total payments, HHI 865
- FX Shoulder Solutions, Inc : $525.5K total payments, HHI 863
- World Class Technology Corporation : $124.1K total payments, HHI 863
- Reflow Medical Inc : $126.3K total payments, HHI 862
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Royal Biologics, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Royal Biologics, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Royal Biologics, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Roche Sequencing Solutions, Inc.
$491.0K 4 recipients
Compare payment profiles
Dilon Technologies, Inc.
$494.5K 1,797 recipients
Compare payment profiles
Antares Pharma, Inc.
$489.5K 19,224 recipients
Compare payment profiles
Theratechnologies Inc.
$486.8K 3,100 recipients
Compare payment profiles
Prismatik Dentalcraft, Inc.
$485.7K 149 recipients
Compare payment profiles
Put this to use
Royal Biologics, Inc. ranks #765 of 1,925 by all-tracks total payments, led by "Royalty or License".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Royalty or License" spend across every manufacturer, not just Royal Biologics, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.